The New SARS-CoV-2 Variants and Their Epidemiological Impact in Mexico

Overview

Journal mBio

Publisher American Society for Microbiology

Specialty Microbiology

Date 2022 Aug 16

PMID 35972143

Authors

Rodrigo Garcia-Lopez

Estibalitz Laresgoiti-Servitje

Roselyn Lemus-Martin

Alejandro Sanchez-Flores

Carlos Sanders-Velez

Affiliations

Soon will be listed here.

Abstract

The COVID-19 disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus started its deadly journey into a global pandemic in Wuhan, China, in December 2019, where it was first isolated. Subsequently, multiple variants of the virus have been identified worldwide. In this review, we discuss the overall landscape of the pandemic in Mexico, including its most prevalent variants, their surveillance at a genomic level, and how they impacted the epidemiology of the disease. We also evaluate the heterologous vaccination in Mexico and how it may have influenced group immunity and helped mitigate the pandemic. Finally, we present an integrated view that could help us to understand the pandemic and serve as an example of the situation in Latin America.

Citing Articles

Epidemiological characterization of COVID-19 in children under 18 years old in Mexico: an analysis of the pandemic.

Takane-Cabrera I, Ortega-Vargas F, Diaz-Torres I, Herrera-Gonzalez A, Villa A, Garcia-Leon M Front Pediatr. 2025; 12():1440107.

PMID: 39840319 PMC: 11745888. DOI: 10.3389/fped.2024.1440107.

Genomic Surveillance of SARS-CoV-2 in México: Three Years since Wuhan, China's First Reported Case.

Lira-Morales J, Lopez-Cuevas O, Medrano-Felix J, Gonzalez-Gomez J, Gonzalez-Lopez I, Castro-Del Campo N Viruses. 2023; 15(11).

PMID: 38005903 PMC: 10674944. DOI: 10.3390/v15112223.

Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).

Chrysostomou A, Vrancken B, Haralambous C, Alexandrou M, Gregoriou I, Ioannides M Viruses. 2023; 15(9).

PMID: 37766339 PMC: 10535466. DOI: 10.3390/v15091933.

References

Plante J, Liu Y, Liu J, Xia H, Johnson B, Lokugamage K . Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020; 592(7852):116-121. PMC: 8158177. DOI: 10.1038/s41586-020-2895-3. View

Patel A, Jernigan D . Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(5):140-146. PMC: 7004396. DOI: 10.15585/mmwr.mm6905e1. View

Freed N, Vlkova M, Faisal M, Silander O . Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Methods Protoc. 2020; 5(1):bpaa014. PMC: 7454405. DOI: 10.1093/biomethods/bpaa014. View

Taboada B, Zarate S, Isa P, Boukadida C, Vazquez-Perez J, Munoz-Medina J . Genetic Analysis of SARS-CoV-2 Variants in Mexico during the First Year of the COVID-19 Pandemic. Viruses. 2021; 13(11). PMC: 8622467. DOI: 10.3390/v13112161. View

Justo Arevalo S, Zapata Sifuentes D, Huallpa C, Landa Bianchi G, Castillo Chavez A, Garavito-Salini Casas R . Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures. Sci Rep. 2021; 11(1):17755. PMC: 8423746. DOI: 10.1038/s41598-021-97267-7. View

Rambaut A, Holmes E, OToole A, Hill V, McCrone J, Ruis C . A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020; 5(11):1403-1407. PMC: 7610519. DOI: 10.1038/s41564-020-0770-5. View

Gohl D, Vangay P, Garbe J, MacLean A, Hauge A, Becker A . Systematic improvement of amplicon marker gene methods for increased accuracy in microbiome studies. Nat Biotechnol. 2016; 34(9):942-9. DOI: 10.1038/nbt.3601. View

She J, Liu L, Liu W . COVID-19 epidemic: Disease characteristics in children. J Med Virol. 2020; 92(7):747-754. PMC: 7228385. DOI: 10.1002/jmv.25807. View

Chen Z, Azman A, Chen X, Zou J, Tian Y, Sun R . Global landscape of SARS-CoV-2 genomic surveillance and data sharing. Nat Genet. 2022; 54(4):499-507. PMC: 9005350. DOI: 10.1038/s41588-022-01033-y. View

10.

Recalcati S . Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020; 34(5):e212-e213. DOI: 10.1111/jdv.16387. View

11.

Dinnes J, Deeks J, Berhane S, Taylor M, Adriano A, Davenport C . Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021; 3:CD013705. PMC: 8078597. DOI: 10.1002/14651858.CD013705.pub2. View

12.

Gohl D, Garbe J, Grady P, Daniel J, Watson R, Auch B . A rapid, cost-effective tailed amplicon method for sequencing SARS-CoV-2. BMC Genomics. 2020; 21(1):863. PMC: 7716288. DOI: 10.1186/s12864-020-07283-6. View

13.

Bayati A, Kumar R, Francis V, McPherson P . SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem. 2021; 296:100306. PMC: 7816624. DOI: 10.1016/j.jbc.2021.100306. View

14.

Robson F, Khan K, Le T, Paris C, Demirbag S, Barfuss P . Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Mol Cell. 2020; 79(5):710-727. PMC: 7402271. DOI: 10.1016/j.molcel.2020.07.027. View

15.

Brandal L, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U . Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021; 26(50). PMC: 8728491. DOI: 10.2807/1560-7917.ES.2021.26.50.2101147. View

16.

Moghadas S, Sah P, Shoukat A, Meyers L, Galvani A . Population Immunity Against COVID-19 in the United States. Ann Intern Med. 2021; 174(11):1586-1591. PMC: 8442744. DOI: 10.7326/M21-2721. View

17.

Struyf T, Deeks J, Dinnes J, Takwoingi Y, Davenport C, Leeflang M . Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022; 5:CD013665. PMC: 9121352. DOI: 10.1002/14651858.CD013665.pub3. View

18.

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

19.

Martinez M, Barrientos-Gutierrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero M, Gaona-Pineda E . . Salud Publica Mex. 2022; 63(6, Nov-Dic):813-818. DOI: 10.21149/13348. View

20.

Zhou H, Yang J, Zhou C, Chen B, Fang H, Chen S . A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV. Front Med (Lausanne). 2021; 8:628370. PMC: 8688360. DOI: 10.3389/fmed.2021.628370. View